

**ASX Release**

**Date:** 4 September 2008

**Subject:** Appointment of Mr Paul Hopper as Non-Executive Director

---

Viralytics is pleased to announce the appointment of Los Angeles based Mr Paul Hopper to our board of directors. Mr Hopper has over 20 years experience in the management and funding of biotechnology and healthcare public companies with extensive capital markets experience with over \$200 million in equity & debt raisings in Australia, Asia, US and Europe.

His sector experience has covered a number of therapeutic areas including anti-bacterials, medical devices, antibodies, inflammation and oncology, with a particular emphasis on cancer vaccines. He is the founder and Director of a private US biotech which is expected to enter US Phase 3 clinical trials for a melanoma cancer vaccine in late 2009. Paul is also a Director of Boston based pSivida Corp (NASDAQ:PSDV) a drug delivery company and Somnomed Limited (ASX:SOM) which globally manufactures and markets a dental device for sleep disorders. He is a consultant to the Santa Monica merchant bank Cappello Capital and New York life-sciences investment bank BIO:IB Inc.

Mr Hopper has served on the Boards of many listed biotech and healthcare companies including as Executive Chairman of Bone Medical Limited, Director of Advanced Biotherapy Inc, Managing Director of Australian Cancer Technology Limited, and Director of Medaire Ltd. He was the co-founder and Managing Director of Alpha Healthcare Limited.

Mr Hopper will be integral in the future funding and commercialisation activities of the business and brings a wealth of relevant experience for the growth the company is undertaking.

Bryan Dulhunty  
Chairman

---

**About Viralytics Ltd.**

Viralytics is listed on the Australian Stock Exchange (ASX code: VLA), Viralytics ADR trades under VRACY on the OTC market in the USA. Viralytics' principal asset is the intellectual property relating to CAVATAK™, an Oncolytic Virus technology. CAVATAK™ is the trade name for Viralytics' proprietary formulation of the Coxsackievirus Type A21 (CVA21). CVA21 is a human virus that occurs naturally in the community. CVA21 attaches to the outside of a cell, using a specific 'receptor' on the cell's surface (like a key fitting a lock). CVA21 uses two receptors to infect cells, intercellular adhesion molecule-1 (ICAM-1) and/or decay accelerating factor (DAF). Both of these receptor proteins have been demonstrated to be highly expressed on multiple cancer types, including: melanoma, prostate cancer, breast cancer, multiple myeloma and others.

For personal use only